ZA883115B - Treatment of diabetes - Google Patents

Treatment of diabetes

Info

Publication number
ZA883115B
ZA883115B ZA883115A ZA883115A ZA883115B ZA 883115 B ZA883115 B ZA 883115B ZA 883115 A ZA883115 A ZA 883115A ZA 883115 A ZA883115 A ZA 883115A ZA 883115 B ZA883115 B ZA 883115B
Authority
ZA
South Africa
Prior art keywords
diabetes
treatment
fluoxetine
mammals
found
Prior art date
Application number
ZA883115A
Other languages
English (en)
Inventor
David Taiwai Wong
Taiwai Wong David
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA883115B publication Critical patent/ZA883115B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA883115A 1987-05-04 1988-05-02 Treatment of diabetes ZA883115B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4550987A 1987-05-04 1987-05-04

Publications (1)

Publication Number Publication Date
ZA883115B true ZA883115B (en) 1990-01-31

Family

ID=21938301

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA883115A ZA883115B (en) 1987-05-04 1988-05-02 Treatment of diabetes

Country Status (11)

Country Link
EP (1) EP0294028B1 (de)
JP (1) JP2721507B2 (de)
KR (1) KR880013555A (de)
AT (1) ATE93721T1 (de)
AU (1) AU596296B2 (de)
DE (1) DE3883606T2 (de)
DK (1) DK238588A (de)
ES (1) ES2058272T3 (de)
HK (1) HK19595A (de)
PH (1) PH23901A (de)
ZA (1) ZA883115B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449562A3 (en) * 1990-03-29 1992-03-18 Eli Lilly And Company Use of r-fluoxetine as selective serotonin ic-receptor ligands
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
ES2761812T3 (es) * 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
EA201590047A1 (ru) 2012-07-31 2015-09-30 Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. Применение флуоксетина для увеличения мясной и молочной продуктивности
EA201590044A1 (ru) 2012-07-31 2015-09-30 Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. Применение флуоксетина у животных
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
ZA861211B (en) * 1985-02-25 1987-10-28 Lilly Co Eli Analgesic composition

Also Published As

Publication number Publication date
EP0294028A3 (en) 1990-05-02
EP0294028A2 (de) 1988-12-07
HK19595A (en) 1995-02-17
DE3883606D1 (de) 1993-10-07
DE3883606T2 (de) 1994-01-20
AU1553388A (en) 1988-11-10
ATE93721T1 (de) 1993-09-15
AU596296B2 (en) 1990-04-26
JPS63284126A (ja) 1988-11-21
DK238588A (da) 1988-11-05
ES2058272T3 (es) 1994-11-01
PH23901A (en) 1989-12-18
KR880013555A (ko) 1988-12-21
DK238588D0 (da) 1988-05-03
EP0294028B1 (de) 1993-09-01
JP2721507B2 (ja) 1998-03-04

Similar Documents

Publication Publication Date Title
JPS5791915A (en) Novel lipid composition useful for dietetics, resuscitation and treatment
PH23901A (en) Treatment of diabetes using fluoxetine
ZA859286B (en) Novel treatment
IE882529L (en) Platinum Coordination Compound
EP0310893A3 (en) Vulcanizable fluororubber composition
GB2198451B (en) Briquette treatment process
GB2158112B (en) Treatment process for utilization of rubber wood
GB8826449D0 (en) Process for treating leather
GB2206821B (en) Improvements relating to surface treatment
ZA884799B (en) Novel treatment
EP0238765A3 (en) 2,2-diphenoxy-n,n-dimethylaminoethane for improving cerebral oxygenation
GB8622419D0 (en) Treatment/therapy for diabetes sufferes
ZA883322B (en) Yeast treatment process
GB8511797D0 (en) Gassifier process liquor treatment scheme
GB8718587D0 (en) Treatment
GB8716534D0 (en) Treatment
GB8712239D0 (en) Treatment
GB8719190D0 (en) Treatment
GB8716648D0 (en) Treatment
GB8711457D0 (en) Treatment
GB8726717D0 (en) Treatment
GB8719189D0 (en) Treatment
GB8719874D0 (en) Treatment
GB8724439D0 (en) Treatment
GB8712241D0 (en) Treatment